Highbridge Capital Management’s Acceleron Pharma XLRN Stock Holding History

Highbridge Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-20,100	Closed	-$751K	–	2089
2017 Q3	$751K	Buy	+20,100	New	+$698K	0.01%	720
2016 Q2	–	Sell	-30,600	Closed	-$808K	–	1871
2016 Q1	$808K	Buy	+30,600	New	+$890K	0.01%	802
2015 Q2	–	Sell	-20,200	Closed	-$769K	–	1755
2015 Q1	$769K	Sell	20,200 -31,600	-61%	-$1.26M	0.01%	832
2014 Q4	$2.02M	Buy	51,800 +16,400	+46%	+$572K	0.03%	475
2014 Q3	$1.07M	Buy	+35,400	New	+$997K	0.01%	642

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Highbridge Capital Management's XLRN Position: Q2 2017 in Review

Highbridge Capital Management sold out of Acceleron Pharma (XLRN) in Q2 2017, closing a stake of 33,510 shares — an estimated $887K sold.

Highbridge Capital Management first reported a position in XLRN in Q2 2014 and held it in 5 quarters. The position peaked at $887K in Q1 2017. 128 funds tracked by Wall St. Rank hold XLRN as of Q2 2017.

Highbridge Capital Management reported no remaining Acceleron Pharma position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 33,510 Acceleron Pharma shares in Q2 2017, an estimated $887K.
Highbridge Capital Management first reported a position in Acceleron Pharma in Q2 2014 and held it in 5 quarters.
Highbridge Capital Management's Acceleron Pharma position peaked at $887K in Q1 2017.
128 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.